<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822547</url>
  </required_header>
  <id_info>
    <org_study_id>ML29378</org_study_id>
    <nct_id>NCT02822547</nct_id>
  </id_info>
  <brief_title>Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults</brief_title>
  <official_title>Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will receive Peginterferon alfa-2a according to the standard medical practice but
      the observation period is 12 weeks
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion subjects with HBsAg ≤ 20,000 IU/mL at 12 week treatment of PEG-IFN in HBeAg-positive Chronic Hepatitis B</measure>
    <time_frame>12 week from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion subjects with any decline of HBsAg and/or HBV DNA decline more than 2 log copies/ml at 12 week treatment of PEG-IFN in HBeAg-negative CHB</measure>
    <time_frame>12 week from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of HBV DNA at Week 12 from baseline</measure>
    <time_frame>12 week from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of HBsAg at Week 4, 8, 12 from baseline</measure>
    <time_frame>4, 8, 12 week from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of ALT at week 4, 8, 12 from baseline</measure>
    <time_frame>4, 8, 12 week from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of HBV DNA undetectable level (&lt; 60 IU/mL, approximately 300 copies/mL) at week 12</measure>
    <time_frame>12 week from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">253</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Peginterferon alfa-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Patients will receive Peginterferon alfa-2a according to the standard medical practice</description>
    <arm_group_label>Peginterferon alfa-2a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of HBsAg positive for more than 6 months

          -  HBeAg-positive or HBeAg-negative within 8 weeks

          -  Serum AST or ALT ≥ 80 IU/L

          -  HBe-Ag positive patients: Serum HBV DNA ≥ 1.0 X 10^5 copies/mL (or 20,000 IU/mL)

          -  HBeAg-negative patients: serum HBV DNA ≥ 1.0 X 10^4 copies/mL(or 2,000 IU/mL)

        Exclusion Criteria:

          -  History of antiviral therapy for Chronic hepatitis B within 6 months of study
             enrollment

          -  Prior treatment of interferon

          -  Presence of viral coinfections (hepatitis C, hepatitis delta, or human
             immunodeficiency virus)

          -  Other chronic liver disease or decompensated liver disease

          -  platelet&lt;90,000/mm3 or absolute neutrophil count &lt; 1,500 mm3

          -  Pregnant or lactating woman

          -  History of Organ transplantation

          -  Treatment with immunosuppressive/immunomodulatory agents within 6 months prior to
             study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Hoon Ahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Hoon Ahn</last_name>
    <phone>82-2-2228-1936</phone>
    <email>ahnsh@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Hoon Ahn, M.D.Ph.D</last_name>
      <phone>+82-11-419-8087</phone>
      <email>ahnsh@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>Jun Yong Park, M.D</last_name>
      <phone>+82-10-8353-0670</phone>
      <email>drpjy@yuhs.ac</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Yong Park, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Sang Hoon Ahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

